Lumito intends to carry out a rights issue of approximately SEK 30 million, subject to approval by an Extraordinary General Meeting, with the objective of capitalising on the company’s commercial momentum and creating long-term value.
Lumito is a Swedish medical technology company within digital tissue analysis that has developed a new technology for analysing tissue samples. With its product SCIZYS, intended for research and development, biomarkers can be measured more precisely and at lower levels than with many traditional methods.
The challenge
Current methods make it difficult to reliably measure biomarkers at low levels, which may result in subjective interpretations and, consequently, uncertain decision-making in research and development.
Lumito’s solution
SCIZYS enables highly sensitive and quantifiable analysis, delivering more accurate and reproducible measurements.
Effect
More reliable analyses can support better decision-making in drug development – for example by reducing project risk, improving patient selection and thereby increasing the likelihood of successful studies.
Value
This can ultimately contribute to more precise treatments and more efficient use of healthcare resources, benefiting both patients and society.
After several years of intensive product development, Lumito is now in an early commercial phase with its product SCIZYS, targeting research and drug development.
During the beginning of 2026, the company has, among other things:
During 2026–2027, the focus is on increasing the commercial use of SCIZYS and building a scalable business through partnerships, customer projects and recurring revenues.
This includes, among other things:
Lumito’s business model is designed to enable capital-efficient and scalable growth, with a focus on recurring revenues.
Partnership-based go-to-market
The company collaborates with contract research organisations (CROs), which conduct studies for pharmaceutical companies and integrate SCIZYS into their existing services. Through this model, Lumito gains access to established customer relationships without the need for an extensive in-house sales organisation.
Recurring revenue streams
Revenue is generated through the sale of reagent kits as well as through the Scan-as-a-Service offering, contributing to a growing base of recurring revenue as usage increases.
Positioning towards pharmaceutical companies
SCIZYS is positioned as a tool in drug development, particularly in areas where there is a need to analyse biomarkers with high sensitivity.
Strategic partnerships
Collaborations with players within tissue analysis and diagnostics strengthen the offering, increase market presence and contribute to broader commercial potential.
SCIZYS is a platform that can be used to analyse a wide range of biomarkers in tissue samples. This means the technology can be applied across multiple research areas and projects, creating the conditions for broader market presence and several parallel commercial opportunities.
This flexibility makes it possible to initially focus on research and drug development, while gradually building value through new applications and partnerships over time.
In the longer term, there is also potential to further develop the technology towards clinical diagnostics, where more quantifiable and objective analyses can contribute to more data-driven and personalised healthcare.
Lumito operates at the intersection of precision medicine, digital pathology and advanced biomarker analysis – three areas driven by strong long-term growth trends in global healthcare and drug development.
The company’s technology addresses a fundamental challenge in tissue analysis: the ability to detect and quantify biological signals with high sensitivity and reproducibility. Through SCIZYS, researchers and drug developers can gain access to more detailed information from tissue samples, supporting improved decision-making in research, development and future patient treatment.
After several years of product development, Lumito is now in an early commercialisation phase. The company has initiated collaborations with CRO players, is conducting pilot projects with leading researchers and is actively working to integrate SCIZYS into customer workflows. At the same time, a growing body of scientific evidence is being built through studies, publications and collaborations with internationally recognised experts.
Lumito’s strategy is to create value through a combination of commercial growth, scientific validation and strategic partnerships. This strengthens the company’s position in the global tissue analysis ecosystem and, over time, opens up opportunities for larger commercial collaborations and other strategic alternatives.
A unique technology for next-generation tissue analysis
Lumito has developed SCIZYS, a patented analysis platform that enables more sensitive, higher-contrast and objective visualisation of biomarkers in tissue samples. Through the company’s proprietary UCNP technology, biological signals can be identified with high precision and low background noise, creating new opportunities in both drug development and digital pathology.
Positioned in two high-growth markets
Demand for advanced analytical tools is driven by the global shift towards precision medicine, biomarker-driven therapies and the digitalisation of pathology laboratories. Lumito addresses needs in both drug development and tissue diagnostics – markets expected to grow over the long term.
From development company to commercial phase
During 2025 and 2026, Lumito has taken important steps in its commercialisation journey, with initial customer orders, established CRO collaborations, pilot projects and initial revenue generation. The company has thus passed an important milestone in transitioning from technology development to commercial market engagement.
A scalable business model with recurring revenue
Lumito’s business model combines the sale and leasing of scanners with recurring revenues from reagent kits and Scan-as-a-Service. As customers integrate SCIZYS into their workflows, the potential for recurring use and long-term customer relationships increases.
Strategic partnerships create leverage
The company’s strategy is built on collaborations with CROs, researchers, pharmaceutical companies and leading players in tissue analysis. Through these partnerships, Lumito can efficiently reach the market, generate scientific evidence and achieve commercial validation without building an extensive in-house global sales organisation.
Strong position in future cancer diagnostics
Lumito focuses particularly on applications where high sensitivity is critical, such as the detection of low-expressed biomarkers like HER2. The ability to identify more treatable patients can create significant value for drug developers, particularly within antibody-drug conjugates (ADCs).
Patented platform with global potential
SCIZYS is based on a protected technology platform with potential applications across multiple research and diagnostic fields. The combination of technical differentiation, a growing evidence base and commercial collaborations creates favourable conditions for long-term value creation.